IMUX

Upcoming Conferences: Immunic, Inc. will participate in the American Academy of Neurology Annual Meeting and German Biotech Days in April 2025, showcasing their lead asset, vidofludimus calcium (IMU-838), which is in late-stage clinical trials for multiple sclerosis.

Company Overview: Immunic focuses on developing orally administered therapies for chronic inflammatory and autoimmune diseases, with additional programs targeting gastrointestinal diseases and a strong emphasis on research and development.

Analyst Ratings: Immunic (IMUX) received a Buy rating and a price target of $1.20 from William Blair analyst Matt Phipps, while the stock has an overall Strong Buy consensus with a higher price target of $12.25 from analysts.

Market Performance: The company's shares closed at $1.20, with a one-year high of $2.11 and a low of $0.92, indicating significant potential upside in the market.

Immunic's Conference Participation: Immunic, Inc. will present two abstracts at the 34th Annual Meeting of the Society for Virology in Hamburg, Germany, focusing on their antiviral therapies, and will also participate in the Leerink Partners Global Healthcare Conference in Miami with a fireside chat by CEO Daniel Vitt.

Company Overview and Pipeline: Immunic is developing small molecule therapies for chronic inflammatory and autoimmune diseases, with its lead program, vidofludimus calcium, currently in clinical trials for multiple sclerosis and ulcerative colitis, while also exploring other gastrointestinal disease treatments.

Vidofludimus Calcium's Potential: Immunic, Inc. presented data on vidofludimus calcium at the ACTRIMS Forum 2025, highlighting its neuroprotective effects through Nurr1 activation and its promise as a treatment for progressive multiple sclerosis (MS), with top-line data from the Phase 2 CALLIPER trial expected in April.

Company Overview: Immunic, Inc. is developing orally administered therapies for chronic inflammatory and autoimmune diseases, with vidofludimus calcium currently in clinical trials for relapsing and progressive MS, demonstrating favorable pharmacokinetics and safety profiles.

Analyst Ratings: William Wood from B.Riley Financial maintains a Buy rating on Immunic (IMUX) with a price target of $6.00, while the overall analyst consensus suggests a Strong Buy with an average price target of $7.00, indicating a potential upside of 451.18%.

Financial Performance: Immunic reported a quarterly GAAP net loss of $24.37 million for the quarter ending September 30, which is slightly higher than the $22.77 million loss reported in the same period last year.

Upcoming Conferences: Immunic, Inc. will participate in several investor and scientific conferences throughout February 2025, including the BIO CEO & Investor Conference, Oppenheimer Healthcare Life Sciences Conference, ECCO Congress, Neuroimmunology Drug Development Summit, and ACTRIMS Forum, where they will present findings on their therapies for chronic inflammatory and autoimmune diseases.

Focus on Therapies: The company is developing orally administered small molecule therapies, notably vidofludimus calcium (IMU-838) for multiple sclerosis and IMU-856 targeting gastrointestinal diseases, with ongoing clinical trials and presentations scheduled to share their research outcomes.

Upcoming Clinical Data: Immunic, Inc. is set to report top-line data from its Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (PMS) in April 2025, while also confirming positive interim results from its Phase 3 ENSURE trials for relapsing multiple sclerosis (RMS), expected to complete by 2026.

Corporate Developments: The company has strengthened its management team with key hires and announced a three-tranche private placement totaling up to $240 million to extend its cash runway into the third quarter of 2025.

Analyst Ratings: Analysts have expressed bullish sentiments for Actinium Pharmaceuticals, NRX Pharmaceuticals, and Immunic, with all three companies receiving "Buy" ratings and significant upside potential in their price targets.

Price Targets and Performance: Actinium has a target of $5.75 (307.8% upside), NRX is set at $31.33, and Immunic has a target of $13.17 (1025.6% upside), indicating strong confidence in their future performance despite current low share prices.

Company Announcement: Immunic, Inc. will participate in the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024, with CEO Daniel Vitt and other executives engaging in a fireside chat and one-on-one investor meetings.

Clinical Development: The company is advancing its lead drug candidate, vidofludimus calcium (IMU-838), through phase 3 and phase 2 trials for multiple sclerosis and has additional therapies targeting gastrointestinal diseases in development.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects you with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

Clinical Trial Results: Immunic, Inc. announced positive results from its Phase 1/1b clinical trial of IMU-856, a small molecule modulator targeting SIRT6, showing safety and efficacy in improving intestinal barrier function in celiac disease patients.

Future Implications: The promising data suggests that IMU-856 could represent a novel oral therapy for celiac disease and potentially other gastrointestinal disorders, warranting further clinical investigation.

Clinical Trial Results: Immunic, Inc. announced positive results from its Phase 1/1b clinical trial of IMU-856, a small molecule modulator targeting SIRT6, showing safety and efficacy in improving intestinal barrier function in celiac disease patients.

Future Implications: The promising data suggests that IMU-856 could represent a novel oral therapy for celiac disease and potentially other gastrointestinal disorders, warranting further clinical investigation.

Earnings Call Overview: Immunic, Inc. held its Q3 2024 earnings conference call on November 7, 2024, featuring key executives including CEO Dr. Daniel Vitt and CFO Glenn Whaley, discussing the company's financial performance and future outlook.

Forward-Looking Statements Warning: The presentation included forward-looking statements that involve risks and uncertainties, with a reminder for participants to refer to Immunic's SEC filings for detailed risk factors affecting the company's results.

Management and Financial Updates: Immunic Inc has strengthened its leadership team and reported a net loss of approximately $24.4 million for the quarter, while also achieving positive interim results in its phase three clinical trial for multiple sclerosis and maintaining a strong cash position of $59.1 million.

Drug Development and Partnerships: The company showcased promising data for its drug candidate, vlu calcium, at the EAMS Congress, highlighting its potential in treating multiple sclerosis, and is actively pursuing partnerships with pharmaceutical companies to enhance funding opportunities amidst significant competition in the market.

Real-time Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them make informed decisions daily.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and alerts generated by Benzinga reporters.

Positive Clinical Trial Updates: Immunic, Inc. announced that the Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis have been confirmed to continue without futility, with top-line data from the Phase 2 CALLIPER trial expected in April 2025.

Financial Overview: The company reported a net loss of approximately $24.4 million for Q3 2024, with cash reserves of $59.1 million, sufficient to fund operations into Q3 2025.

Upcoming Webcast Announcement: Immunic, Inc. will release its third-quarter financial results on November 7, 2024, followed by a webcast at 8:00 am ET for participants who register in advance.

Company Overview and Drug Development: Immunic is focused on developing small molecule therapies for chronic inflammatory and autoimmune diseases, with key programs including vidofludimus calcium for multiple sclerosis and IMU-856 targeting gastrointestinal diseases.

Upcoming Conferences: Immunic, Inc. will participate in several industry and investor conferences throughout November, including BIO-Europe in Stockholm, a symposium on immuno-mediated diseases in Florence, and the Jefferies London Healthcare Conference.

Clinical Developments: The company is advancing its clinical pipeline with IMU-856 for celiac disease and vidofludimus calcium (IMU-838) for multiple sclerosis, while also preparing for future trials and presentations at various events.

Real-time Trading Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them stay updated with real-time news alerts.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.

Positive Interim Analysis Results: Immunic, Inc. announced that the interim futility analysis of its Phase 3 ENSURE program for IMU-838 in treating relapsing multiple sclerosis showed no futility, allowing the trials to continue as planned.

Study Timeline: The ENSURE studies, which include ENSURE-1 and ENSURE-2, are on track for completion by 2026.